3,464
Views
40
CrossRef citations to date
0
Altmetric
Research Article

Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease

, , , , , , , , & show all
Pages 1147-1155 | Received 21 May 2020, Accepted 13 Jul 2020, Published online: 30 Jul 2020

References

  • Amjadi M, Sheykhansari S, Nelson BJ, Sitti M. (2018). Recent advances in wearable transdermal delivery systems. Adv Mater 30:1–19.
  • Association A. (2017). Alzheimer's disease facts and figures. Alzheimer's Dement 13:325–73.
  • Association A. (2018). Alzheimer's disease facts and figures. Alzheimer's Dement 14:367–429.
  • Brown MB, Jones SA. (2005). Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 19:308–18.
  • Chen F, Yan Q, Yu Y, Wu MX. (2017). BCG vaccine powder-laden and dissolvable microneedle arrays for lesion-free vaccination. J Control Release 255:36–44.
  • Chen M-C, Huang S-F, Lai K-Y, Ling M-H. (2013). Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination. Biomaterials 34:3077–86.
  • Chen Y, Yang Y, Xian Y, et al. (2020). Multifunctional graphene-oxide-reinforced dissolvable polymeric microneedles for transdermal drug delivery. ACS Appl Mater Interfaces 12:352–60.
  • Choi JT, Park SJ, Park JH. (2018). Microneedles containing cross-linked hyaluronic acid particulates for control of degradation and swelling behaviour after administration into skin. J Drug Target 26:884–94.
  • Chu DF, Fu XQ, Liu WH, et al. (2006). Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm 325:116–23.
  • Dhingra D, Soni K. (2018). Behavioral and biochemical evidences for nootropic activity of boldine in young and aged mice. Biomed Pharmacother 97:895–904.
  • Dillon C, Hughes H, O'Reilly NJ, McLoughlin P. (2017). Formulation and characterisation of dissolving microneedles for the transdermal delivery of therapeutic peptides. Int J Pharm 526:125–136.
  • Eltayib E, Brady AJ, Caffarel-Salvador E, et al. (2016). Hydrogel-forming microneedle arrays: potential for use in minimally-invasive lithium monitoring. Eur J Pharm Biopharm 102:123–31.
  • Ferreira A, Rodrigues M, Fortuna A, et al. (2016). Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology. Phytochem Rev 15:51–85.
  • Foyet HS, Abaissou HHN, Wado E, et al. (2015). Emilia coccinae (SIMS) G extract improves memory impairment, cholinergic dysfunction, and oxidative stress damage in scopolamine-treated rats. BMC Complement Altern Med 15:333.
  • Galimberti D, Scarpini E. (2016). Old and new acetylcholinesterase inhibitors for Alzheimer's disease. Expert Opin Investig Drugs 25:1181–7.
  • Gao Y, Hou MM, Yang RH, et al. (2019). Transdermal delivery of therapeutics through dissolvable gelatin/sucrose films coated on PEGDA microneedle arrays with improved skin permeability. J Mater Chem B 7:7515–24.
  • Hager K, Marahrens A, Kenklies M, et al. (2001). Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 32:275–82.
  • Du H, Liu P, Zhu J, et al. (2011). Hyaluronic acid-based dissolving microneedle patch loaded with methotrexate for improved treatment of psoriasis. ACS Appl Mater Inter 11:43588–98.
  • Kim DS, Choi JT, Kim CB, et al. (2020). Microneedle array patch (MAP) consisting of crosslinked hyaluronic acid nanoparticles for processability and sustained release. Pharm Res 37:11.
  • Kim YC, Park JH, Prausnitz MR. (2012). Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 64:1547–68.
  • Laicher A, Fuchs WS. (1998). Pellet technology sustained release pellets in hard gelatine capsules – a suitable dosage form for theophylline. Arzneimittelforschung 48:540–7.
  • Lee JW, Prausnitz MR. (2018). Drug delivery using microneedle patches: not just for skin. Taylor & Francis 6:541–543.
  • Leone M, Romeijn S, Slütter B, et al. (2020). Hyaluronan molecular weight: effects on dissolution time of dissolving microneedles in the skin and on immunogenicity of antigen. Eur J Pharm Sci 146:105269.
  • Li ZL, He YJ, Deng L, et al. (2020). Correction: a fast-dissolving microneedle array loaded with chitosan nanoparticles to evoke systemic immune responses in mice (vol 66, pg 489, 2020). J Mater Chem B 8:578–79.
  • Migdadi EM, Courtenay AJ, Tekko IA, et al. (2018). Hydrogel-forming microneedles enhance transdermal delivery of metformin hydrochloride. J Control Release 285:142–51.
  • Nguyen TT, Giau VV, Vo TK. (2017). Current advances in transdermal delivery of drugs for Alzheimer's disease. Indian J Pharmacol 49:145–54.
  • Ono A, Ito S, Sakagami S, et al. (2017). Development of novel faster-dissolving microneedle patches for transcutaneous vaccine delivery. Pharmaceutics 9:27.
  • Park Y-H, Ha SK, Choi I, et al. (2016). Fabrication of degradable carboxymethyl cellulose (CMC) microneedle with laser writing and replica molding process for enhancement of transdermal drug delivery. Biotechnol Bioprocess Eng 21:110–8.
  • Peng T, Shi Y, Zhu C, et al. (2019). Huperzine A loaded multiparticulate disintegrating tablet: drug release mechanism of ethyl cellulose microparticles and pharmacokinetic study. Powder Technol 355:649–56.
  • Pérennès F, Marmiroli B, Matteucci M, et al. (2006). Sharp beveled tip hollow microneedle arrays fabricated by LIGA and 3D soft lithography with polyvinyl alcohol. J Micromech Microeng 16:473–9.
  • Perez-Lloret S, Barrantes FJ. (2016). Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease. NPJ Parkinsons Dis 2:16001.
  • Ronnander P, Simon L, Spilgies H, et al. (2018). Dissolving polyvinylpyrrolidone-based microneedle systems for in-vitro delivery of sumatriptan succinate. Eur J Pharm Sci 114:84–92.
  • Selkoe DJ, Hardy J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8:595–608.
  • Sevigny J, Chiao P, Bussière T, et al. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537:50–6.
  • Tsikas D. (2017). Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: analytical and biological challenges. Anal Biochem 524:13–30.
  • van der Maaden K, Jiskoot W, Bouwstra J. (2012). Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 161:645–55.
  • Vorhees CV, Williams MT. (2006). Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848–58.
  • Wang C, Zhang T, Ma H, et al. (2007). Prolonged effects of poly(lactic-co-glycolic acid) microsphere-containing huperzine A on mouse memory dysfunction induced by scopolamine. Basic Clin Pharmacol Toxicol 100:190–5.
  • Wang M, Han YY, Yu XJ, Liang LL, et al. (2020). Upconversion nanoparticle powered microneedle patches for transdermal delivery of siRNA. Adv Healthc Mater 9:11.
  • Wang R, Yan H, Tang XC. (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27:1–26.
  • Wang Y, Chu D, Gu J, et al. (2004). Liquid chromatographic–tandem mass spectrometric method for the quantitation of huperzine A in dog plasma. J Chromatogr B Analyt Technol Biomed Life Sci 803:375–8.
  • Wu C-L, Wen S-H. (2016). A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. Medicine 95:e4593.
  • Wu T, Li CY, Chen M, et al. (2011). Clinic pharmacokinetic profiles of huperzine A following transdermal administration to healthy human volunteers. Chromatographia 74:67–73.
  • Xie D, Xie J, Wang J, et al. (2013). Huperzia serrata (Thunb.) Trev. composition comprising compounded Huperzine A and Huperzine B and methods for preparing it. U.S. Patent No. 8,574,633. Washington, DC: U.S. Patent and Trademark Office.
  • Yan Q, Liu H, Cheng Z, et al. (2017). Immunotherapeutic effect of BCG-polysaccharide nucleic acid powder on Mycobacterium tuberculosis-infected mice using microneedle patches. Drug Deliv 24:1648–53.
  • Ye JC, Zeng S, Zheng GL, Chen GS. (2008). Pharmacokinetics of huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm 356:187–92.
  • Ye Y, Yu J, Wen D, et al. (2018). Polymeric microneedles for transdermal protein delivery. Advanced drug delivery reviews 127:106–18.
  • Yu W, Jiang G, Liu D, et al. (2017). Fabrication of biodegradable composite microneedles based on calcium sulfate and gelatin for transdermal delivery of insulin. Mater Sci Eng C Mater Biol Appl 71:725–34.
  • Zhang XX, Chen GP, Liu YX, et al. (2020). Black phosphorus-loaded separable microneedles as responsive oxygen delivery carriers for wound healing. ACS Nano 14:5901–8.
  • Zhang Z, Wang X, Chen Q, et al. (2002). Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 82:941–4.
  • Zheng W, Xiang Y-Q, Ungvari GS, et al. (2016). Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Shanghai Arch Psychiatry 28:64–71.
  • Zhu X, Gu Y, Wang H. (1999). Comparison of the efficacy between tablet and capsule of huperzine to treat age associated memory impairment by double blind trail method. Chin J Clin Pharm 8:227–9.